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6.1% (n=10) were genotype 3b. 3.0% (n=5) were genotype 1a. n=
01 had genotype 1b. 4.2% (n= 7) had mixed genotype (3a, 3b/1a,
1b, 3a, 3b).
Conclusion: Majority (85.9%) of chronic hepatitis C patients were
genotype 3a which is associated with favorable outcome after 24
weeks of conventional interferon and ribavirin therapy and only
3.0% had genotype 1a in this cohort.
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Background: Alanine aminotransferase is an enzyme produced in
hepatocytes and its raised levels in serum indicate hepatocyte
damage. Furthermore, the number of patients with sustained
viral response (SVR) and with sustained ALT normalization in
non-SVR patients was also signiﬁcantly higher in the combination
therapy versus monotherapy group.
Objectives: To study the effect of Initial ALT levels on predicting
sustained virological response in HCV infected patients getting
conventional Interferon alpha 2b and Ribavirin combination ther-
apy in the Gastroenterology and Hepatology division of Holy
Family Hospital under the National program for prevention and
control of hepatitis in Pakistan.
Methodology: Retrospective observational study on the records
of patients diagnosed as HCV positive coming for conventional
Interferon and Ribavirin therapy to the Gastroenterology and
Hepatology division of Holy Family Hospital under the National
program for prevention and control of hepatitis in Pakistan. It is
to be noted that pathology lab at Holy Family Hospital takes a
value less than or equal to 45 U/L as normal.
Results (n=89): Group I: ALT ≤ 45
– n=25; SVR achieved 80.0%, n=20; Relapser 20.0%, n=05
Group II: ALT 45-90
– n=33; SVR achieved 81.8%, n=27; Relapser 18.8%, n=06
Group III: ALT > 90
– n=31; SVR achieved 64.5%, n=20; Relapser 35.5%, n=11
Conclusion: It was concluded that there is signiﬁcant PCR neg-
ativity at 24 weeks in patients with ALT levels upto 90 U/L as
compared to the patients with ALT levels more than 90 U/L.
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Background/Aim: Alanine aminotransferase is an enzyme pro-
duced in hepatocytes and its raised levels in serum indicate
hepatocyte damage. Conventional Interferon being an immune
modulator and Ribavirin being a nucleoside analogue antiviral
drug is believed to suppress hepatocyte damage and inﬂamma-
tion and so decrease the levels of ALT in serum of patients with
high ALT levels undergoing combination therapy. The aim is to
study the changes in ALT levels in HCV infected patients get-
ting conventional Interferon alpha 2b and Ribavirin combination
therapy
Methodology: Retrospective observational study on the records
of patients diagnosed as HCV positive coming for conventional
Interferon and Ribavirin therapy to the Gastroenterology and
Hepatology division of Holy Family Hospital under the National
program for prevention and control of hepatitis in Pakistan. It is
to be noted that pathology lab at Holy Family Hospital takes a
value less than or equal to 45 U/L as normal.
Results (n=663): At the start of combination therapy the mean
ALT levels were 80.20 with std. deviation of 66.176 and after
06 months of therapy the mean ALT levels were 41.47 with std.
deviation of 42.194. Furthermore, 461 patients had ALT levels
more than 45 before starting combination therapy and out of
these 461 patients 69.6%, n= 321 had normalization of ALT levels
(<45 IU/L).
Conclusion: It was concluded that use of Conventional Interferon
alpha 2b and Ribavirin combination therapy in patients with
chronic Hepatitis C, ALT levels show trend towards Normaliza-
tion.
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Background: Thrombocytopenia is one of the major adverse
effects of IFN-α and ribavirin often leading to dose reduction or
treatment discontinuation. Recent data demonstrated that 4-6%
of patients underwent dose modiﬁcation secondary to thrombo-
cytopenia. Reduction of the dose is recommended at 50,000 cell
count/cmm and discontinuation, if the platelet count drops be-
low 30,000 cell/cmm. It is now a known fact that dose reduction
or interruption of therapy leads to lesser SVR.
Methods: This observational study was conducted in chronic
hepatitis C patients treated with conventional interferon 3 MIU
thrice weekly and ribavirin 400 mg bid for 24 weeks. All patients
had raised ALT levels for last 06 months, had positive PCR for
HCV RNA by real time method and liver biopsy was done. Platelet
counts along with hemoglobin concentration and TLC were moni-
tored in all patients on monthly basis. Data was analyzed by using
SPSS 13.0
Results: Out of 422 patients 15% (n=63) developed thrombocy-
topenia at 12 weeks whereas out of the remaining 359 patients
another 6% (n=22) developed thrombocytopenia at 24 weeks of
therapy. 70 Patients had platelet count in the range of 100-
150,000 cells/cmm. 11 patients had platelet count less than
100,000 cells/cmm and 02 patients had platelet count less than
50,000 cells/cmm.
Conclusion: We conclude that thrombocytopenia is present in a
signiﬁcant number of patients receiving conventional interferon
and ribavirin therapy (15% at week 12 and 6% at week 24). 02
patients needed discontinuation of therapy.
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Background/Aims: Hepatitis C is the most common cause of
Chronic Liver Disease in Pakistan with HCV prevalence of 4%.
Liver Biopsy is done for suitability of treatment based on necroin-
ﬂammatory score (grade) and stage of ﬁbrosis. The aim of this
study is to evaluate the staging and grading of histological
changes on liver biopsy in Chronic Hepatitis C patients and its
correlation with serum ALT levels.
Methods: Retrospective descriptive study on the patient records
at Gastroenterology and Hepatology division of Holy Family Hos-
pital including patients of Chronic Hepatitis C undergoing ﬁrst
liver biopsy with no prior treatment and excluding those with
other indications for biopsy. Data was analyzed using SPSS 13.
